Member Info for LlamaFarmer

Note the bulk of these warrants are Lenders Warrants from Awakn when N.Nelson ( Ex Chairman who gave way for Dennis Purcell ) and 1 other privately lent the business the money to formulate 001, 002 and 014, its not money spaffed on overinflated small cap salaries.

Usually the churn after a placing goes on for a while as people get in, change their mind, want to accept 3 - 10% quick profit and leave, so the shares change hands 2 - 3 times before they find a 'sticky' home, hence the general rule of thumb is 2.5 - 3 times churn.

Because the road map with Solvonis is clearly marked i.e. Phase 3 NHS, Phase 2b FDA and both trials have clearly stated they are on a fast track into instant adoption Nationally in both cases plus the addition of Europe it should make them stickier, quicker.

The BOD all have substantial holdings.

There are some II's with decent holdings and one at 12.36%

There are 1b warrants/options available but of these only 300m are anywhere near worth changing up, the rest are over 60p, so future dilution is minimal.

XViolet.

It's what they do at the moment with 3 x inferior treatments - look it up.

AA meetings,are 'talking therapy' of a kind, no ketamine they rely on sponsors and an affiliation to a higher power.

The beauty of low doseage Ketamine is it allows new neural pathways to open in the brain for a change in behaviour and the patient reprogrammes themselves.

If you go back to the 1960s Richard Nixon reached out to all the European allies and convinced them all to ban, ketamin, lsd, psilocybin as the youth were reprogramming themselves,and refusing to fight the wars that their political masters wanted them to.

It's taken 70 years to relax due to this fear of them hitting recruitment numbers and independent thought, but the overwhelming medical evidence that these drugs can deal with addictive personalities has outweighed and political viewpoints have shifted.

Pamlico Shoals only bought in after a,few things happened.

1. LONDON listing

2.Dennis Purcell of Aisling Capital appointed as Chairman.

3.Phase 3 uk svn 001 and Phase,2b svn 002 FDA and ptsd clinical stage svn 014.

Follow the money.

Then you look into Pamlico Shoals who have just paid 13p for 703m shares to take a seat at the table.

Pamlico shoals filing notices throws up Michael Laymen.

His linked in profile confirms Partner/Ceo status of Pamlico amongst other business interests.

https://capedge.com/company/1942060/pamlico-shoals-capital-llc/filings/chronological

Home

Get To Know Us

Michael Layman



Michael Layman

Board Member

Mr. Layman is a well-established financial industry executive with a track record for driving value and growth for both private and publicly traded companies. Mr. Layman currently serves as General Partner/CEO of Emerald Shoals Targeted Opportunities Fund LP, a hybrid growth fund backed by a network of ultra-high net worth individuals seeking novel opportunities to invest in high-growth catalyst driven companies. Mr. Layman currently serves on the board of directors of American Resources Corporation, NASDAQ, AREC, a met-carbon, and rare earth mining company.  Mr. Layman obtained his Bachelor of Arts degree in business from Otterbein University.

Stamped,

That is the unknown, depends who wants to buy it?

Placed at 13p for 5.908B shares £7.68m market cap.

Value of curing 86% of alcoholics, sufferers of ptsd and drug users?

Is it 6 x £50m market cap? That seems far too low.

60 x at £500m? Would the NHS pay a one of fee of £500m to fix a £3b annually recurring health issue? And then licence it to the USA and Europe?

They'd be a bit silly not to.

Once you look at it like that would a hedge fund not be better off buying it and licensing it to the NHS, USA and EUrope? On an annual licence.

Https://ir.atai.com/news-releases/news-release-details/atai-life-sciences-announces-positive-topline-results-beckley

A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months

- BPL-003 was well-tolerated with no serious or severe adverse events reported

Conclusion: Close, but no cigar

SVN -001

Side effects ( no copy and paste available on morekare website)

3 x low doses of Ketamin, may feel disassociation, out of body experience,any side effects will stop once the treatment has ended.

No surprise that Dennis Purcell saw the stage 11 trial results, noted 001 is double the success rate of any of the 3 market leading AUD treatments with NONE of the side effects.

ACAMPPROSATE

How does acamprosate make you feel?

This medicine may cause some people to be agitated, irritable or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you or your caregiver notice any of these unwanted effects, tell your doctor right away.

OXCARBAZEPINE

Adverse Effects

Some common side effects that patients experience when taking oxcarbazepine are sedation, dizziness, abnormal gait, headache, ataxia, fatigue, confusion, nausea, vomiting, abdominal pain, or rash.

https://www.ncbi.nlm.nih.gov

NALTREXONE

What is the most common side effect of naltrexone?

The most common naltrexone side effects include:

Nausea and vomiting. ...

Dizziness. ...

Sedation. ...

Sleep changes. ...

Injection site reactions (with extended-release injectable use).

This is the current NHS and FDA " stop drinking alcohol " pills ( three treatments, with side effects and some tests removing early stage drinkers ) .

Acamprosate (brand name Campral)

Numerous trials have found that acamprosate is not significantly more efficacious than naltrexone or disulfiram, and the efficacy of acamprosate does not appear to be improved by combining acamprosate with other active medications (eg, naltrexone) or with psychosocial treatment (eg, cognitive-behavioral therapy

At the end of the 6-month treatment and up to 6 months following treatment, there were no significant differences in success (nonlapsed) rates between the three groups. The best outcomes were observed in the acamprosate + behavioral therapy condition (47.6% success rate at end of treatment and 35% success rate at 6-month follow-up) and the placebo + behavioral therapy condition (48% success rate at end of treatment and 32% success rate at 6-month follow-up), as compared with the acamprosate + supportive counseling condition (37.7% success rate at end of treatment and 32% success rate at 6-month follow-up). Other drinking outcomes (eg, rates of moderate, nonheavy drinking) were not reported.

So there is quite a low bar for Svns to get svn -001 over, the 86% seen in the Phase 11 test is an industry game changer

Need to raise funds about now.

Shame,as it looked good a few years ago.

Tricky,

Yes, id say 0.3 - 0.5 on 001 mid term results is fair.

Then full results, roll out into NHS with clear linear pathway for 002 and 014 to do the same and it could go bonkers, if it gets a Big Pharma bid in ( Dennis Purcell connections ) there is nothing else like it available to those that struggle with Alcohol and or PTSD.

Is the cure for Alcohol misuse, PTSD leading on to Drug addiction control worth £1 a share, £2, a fiver? who knows, when the market see's something new with no competition to its product it often goes bonkers and overvalues everything.

Good to see that the different social media forums are slowly starting to become aware of SVNS, the people involved and it's potential.

Once the companies newsflow and interviews start up, around July time this should start to move back up more in line with where it should be, I don't mean the full 3680% growth ;) but a few hundred % on news that 001, 002 and 014 are all on track.

SVN - 001 Maximum cost to Awakn now SVNS has been capped at £800k

What is the value of a Pharma that owns an AUD treatment in the UK, one in the USA and a PTSD treatment in USA and UK?

What is its value once the PTSD treatment is proved up to deal with Fentanyl drug addiction?

Roughly, someone tell me, how many Billions of $ is that business worth?

Maybe that is a question for Dennis Purcell to answer?

CEO Anthony Tennyson - has said excited by early phase 111 results and data.

They should have news by the end of July.

At that point we will see our CHairman Dennis Purcell and Dr David Nutt booked in for interviews to promote these mid point test findings and then the CEO will do another Proactive interview or similar.

What is Dennis Purcells function in this Company? https://www.proactiveinvestors.co.uk/companies/news/1057000/graft-polymer-uk-appoints-biotechnology-industry-leader-dennis-purcell-as-chairman-1057000.html

"Pyschoactive drugs ... we are seeing things that are doing much much better than what's available currently".

"Focused on the life sciences sector"

On mental health - " there's great opportunity in those areas to treat more of the population"

"TO MAKE DEALS and make transactions, make partnerships... to help Anthony and David ... with my background having done a lot of mergers and acquisitions.

There are stocks to skim for 10%, there are others that have a clear route map, supported politically and socially that you hold as it changes lifes.

Not just talking about the drinkers here either.

DV, I was in Mos at 0.042 lows last year, same thing, ncyt at 10p in 2020 same thing couldn't give them away, tlsa 2020 at 36p.

This has got the same look to it with a subtle difference - its not a covid pharma stock, this isn't a seasonal fluctuating flu.

1.So far - the science works - Dr David Nutt - figure head of the Sentia 0% alcohol Spirits brand is leading it.

2.It's an ongoing social problem that isn't going to go away.

Buy them, hold them, wait for More Kare 001 results, then 002 FDA results, then 014 PTSD results, sell them sit back and wait for the next one while you enjoy spending it.

All three programmes have "accelerate" written within them,

001 - it is the NHS ability to speed up results and put it straight into use and protects their data from competitors using it for 8 + 2 years

002 - It is the FDA that conversely lets them use competitors data to speed up the body of results required and offers a pathway straight into use.

014 - "Concept Life Sciences is a UK-based drug discovery CRO, helping global pharma and biotech companies accelerate their drug candidate to clinic by offering integrated drug discovery programs as well as high quality solutions in Biology, Chemistry, ADME/ DMPK, Toxicology and GMP manufacturing".

014 accelerates the clinical stage and then again can go even faster via NHS and/or FDA for PTSD use.

As the PTSD treatment is a gateway drug :) to Drug addiction treatment this is accelerating the earning potential and therefore the interest from Big Pharma.

Who owns Concept Life Sciences? https://www.conceptlifesciences.com/news-and-blog/limerston-capital-aquires-concept-life-sciences

They've already been bought out ... SVNS won't stay independent for long.